These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26320529)

  • 1. [On "2015 Guidelines for Prevention and Treatment of Osteoporosis". The mechanism of bone fragility].
    Saito M
    Clin Calcium; 2015 Sep; 25(9):1301-6. PubMed ID: 26320529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bone metabolism and cardiovascular function update. The estimation of bone material quality in the concept of bone and vascular linkage].
    Saito M; Kida Y; Marumo K
    Clin Calcium; 2014 Jul; 24(7):27-35. PubMed ID: 24976053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [On "2015 Guidelines for Prevention and Treatment of Osteoporosis". Cellular mechanism and etiology of osteoporosis].
    Koga T; Takayanagi H
    Clin Calcium; 2015 Sep; 25(9):1293-300. PubMed ID: 26320528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis.
    Seeman E
    Osteoporos Int; 2003; 14 Suppl 3():S2-8. PubMed ID: 12730770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragility fractures in men with idiopathic osteoporosis are associated with undermineralization of the bone matrix without evidence of increased bone turnover.
    Fratzl-Zelman N; Roschger P; Misof BM; Nawrot-Wawrzyniak K; Pötter-Lang S; Muschitz C; Resch H; Klaushofer K; Zwettler E
    Calcif Tissue Int; 2011 May; 88(5):378-87. PubMed ID: 21318401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoplasmic superoxide causes bone fragility owing to low-turnover osteoporosis and impaired collagen cross-linking.
    Nojiri H; Saita Y; Morikawa D; Kobayashi K; Tsuda C; Miyazaki T; Saito M; Marumo K; Yonezawa I; Kaneko K; Shirasawa T; Shimizu T
    J Bone Miner Res; 2011 Nov; 26(11):2682-94. PubMed ID: 22025246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New mechanisms and targets in the treatment of bone fragility.
    Martin TJ; Seeman E
    Clin Sci (Lond); 2007 Jan; 112(2):77-91. PubMed ID: 17155930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling.
    Riggs BL; Parfitt AM
    J Bone Miner Res; 2005 Feb; 20(2):177-84. PubMed ID: 15647810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture.
    Christiansen P
    APMIS Suppl; 2001; (102):1-52. PubMed ID: 11419022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathomechanics of osteoporoses.
    Frost HM
    Clin Orthop Relat Res; 1985 Nov; (200):198-225. PubMed ID: 3905111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microarchitecture, the key to bone quality.
    Brandi ML
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv3-8. PubMed ID: 19783591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of osteoporosis and fracture.
    Lappe JM
    Nurs Clin North Am; 2001 Sep; 36(3):393-400, vii. PubMed ID: 11532654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Outline of Guidelines 2004 for bone marker in osteoporosis].
    Nishizawa Y
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():37-41. PubMed ID: 18161079
    [No Abstract]   [Full Text] [Related]  

  • 14. [Many issues about bone quality].
    Saito M
    Clin Calcium; 2012 Jun; 22(6):865-9. PubMed ID: 22653026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis.
    Manolagas SC; Jilka RL
    N Engl J Med; 1995 Feb; 332(5):305-11. PubMed ID: 7816067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.
    Tarantino U; Celi M; Feola M; Liuni FM; Resmini G; Iolascon G
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S65-9. PubMed ID: 24046047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The osteoclast, bone remodelling and treatment of metabolic bone disease.
    Boyce BF; Rosenberg E; de Papp AE; Duong LT
    Eur J Clin Invest; 2012 Dec; 42(12):1332-41. PubMed ID: 22998735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A supra-cellular model for coupling of bone resorption to formation during remodeling: lessons from two bone resorption inhibitors affecting bone formation differently.
    Jensen PR; Andersen TL; Pennypacker BL; Duong LT; Engelholm LH; Delaissé JM
    Biochem Biophys Res Commun; 2014 Jan; 443(2):694-9. PubMed ID: 24333871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Daily practice using the guidelines for prevention and treatment of osteoporosis. How do we realize the bone quality in routine practice using Japanese guideline for osteoporosis prevention and treatment?].
    Saito M
    Clin Calcium; 2008 Aug; 18(8):1104-13. PubMed ID: 18677047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis].
    Watanabe R; Okazaki R
    Clin Calcium; 2014 Jan; 24(1):59-67. PubMed ID: 24369281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.